Compile Data Set for Download or QSAR
maximum 50k data
Found 49 Enz. Inhib. hit(s) with all data for entry = 1960
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347773(US9790220, Example 6)
Affinity DataIC50:  8.60nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347772(US9790220, Example 5)
Affinity DataIC50:  14nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347777(US9790220, Example 10)
Affinity DataIC50:  21nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347788(US9790220, Example 21)
Affinity DataIC50:  24nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347786(US9790220, Example 19)
Affinity DataIC50:  33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347775(US9790220, Example 8)
Affinity DataIC50:  34nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347785(US9790220, Example 18)
Affinity DataIC50:  41nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347779(US9790220, Example 12)
Affinity DataIC50:  42nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347769(US9790220, Example 1)
Affinity DataIC50:  43nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347780(US9790220, Example 13)
Affinity DataIC50:  69nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 26 | US9790220, Example 27)
Affinity DataIC50:  71nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347776(US9790220, Example 9)
Affinity DataIC50:  84nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347791(US9790220, Example 24)
Affinity DataIC50:  86nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347787(US9790220, Example 20)
Affinity DataIC50:  100nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347770(US9790220, Example 2)
Affinity DataIC50:  128nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347782(US9790220, Example 15)
Affinity DataIC50:  150nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347771(US9790220, Example 3)
Affinity DataIC50:  170nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347781(US9790220, Example 14)
Affinity DataIC50:  170nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347784(US9790220, Example 17)
Affinity DataIC50:  210nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347790(US9790220, Example 23)
Affinity DataIC50:  290nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347789(US9790220, Example 22)
Affinity DataIC50:  300nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347778(US9790220, Example 11)
Affinity DataIC50:  330nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347774(US9790220, Example 7)
Affinity DataIC50:  540nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347783(US9790220, Example 16)
Affinity DataIC50:  630nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347792(US9790220, Example 25)
Affinity DataIC50:  660nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 26 | US9790220, Example 27)
Affinity DataIC50:  910nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347772(US9790220, Example 5)
Affinity DataIC50:  2.80E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347775(US9790220, Example 8)
Affinity DataIC50:  3.30E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347786(US9790220, Example 19)
Affinity DataIC50:  3.60E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 26 | US9790220, Example 27)
Affinity DataIC50:  6.00E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347785(US9790220, Example 18)
Affinity DataIC50:  8.80E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347784(US9790220, Example 17)
Affinity DataIC50:  9.60E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347792(US9790220, Example 25)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347791(US9790220, Example 24)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347790(US9790220, Example 23)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347789(US9790220, Example 22)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347788(US9790220, Example 21)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347787(US9790220, Example 20)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347782(US9790220, Example 15)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347781(US9790220, Example 14)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347780(US9790220, Example 13)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347779(US9790220, Example 12)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347778(US9790220, Example 11)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347777(US9790220, Example 10)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347776(US9790220, Example 9)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347774(US9790220, Example 7)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347773(US9790220, Example 6)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347771(US9790220, Example 3)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347769(US9790220, Example 1)
Affinity DataIC50: >1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent